by Mybiogate | Feb 25, 2021 | China Market
Author: HE Sheng Recently the CDK4/6 inhibitor Cosela (trilaciclib), developed by G1Therapeutics, was launched in the United States. The inhibitor’s aim is to “decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered... 
by Mybiogate | Feb 9, 2021 | Industrial Park Insights
Hangzhou is the capital of Zhejiang province on the eastern coast of China. It is a city classically known for its natural environment and locations such as the Grand Canal and West Lake. However, Hangzhou is also a bustling commercial center and industrial city. One... 
by Mybiogate | Feb 5, 2021 | Industry Research
Bladder cancer occurs when cells that comprise the urinary bladder begin to grow out of control. Over time, as more cancer cells develop, they can form a tumor and spread to other parts of the body. The most common type of bladder cancer, according to the American... 
by Mybiogate | Feb 4, 2021 | Industry Research
Author: Ginger Ding At the end of 2020, as IPOs and China cross-border transactions reached a record high, Overland Pharmaceuticals announced joint ventures with ADC Therapeutics and Allogene. This announcement occurred just a week after Overland’s debut. The...